Short answer
Revvity (RVTY) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 28, 2025. Quarterly revenue was $699M (up 2.2% year over year) with net income of $47M.
Q3 2025 key financials · XBRL
- Revenue
- $699M
- +2.2% YoY · −3.0% QoQ
- Net income
- $47M
- −50.6% YoY · −13.5% QoQ
- Operating margin
- 11.7%
- EPS (diluted)
- $0.40
- −47.4% YoY · −13.0% QoQ
Source: XBRL data from the Revvity (RVTY) Q3 2025 10-Q on SEC EDGAR. USD.
Revvity Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $698.9M for Q3 FY25, up 2% YoY from $684.0M; Life Sciences up 1% to $342.8M, Diagnostics up 3% to $356.1M
- Gross margin 53.6% for Q3 FY25, down 2.66 pts YoY from 56.3%, cost of revenue 46.4% vs 43.7% YoY due to tariffs and FX impact
- Life Sciences segment operating income $101.0M, down 9% YoY; Diagnostics segment operating income $89.4M, down 5% YoY
- Operating cash flow $407.0M for nine months FY25, down $82.5M YoY; increased stock repurchases $652.5M vs $184.4M prior year
- Management expects ~20% effective tax rate FY25; ongoing tariff impact prompting mitigation strategies; new $1B share repurchase authorized through 2027
Risk Factors
- New risk: Increased customer spending caution due to recent U.S. funding and regulatory uncertainties undermining purchase timing and volumes
- Updated risk: More costly or less effective risk mitigation due to recent market developments affecting hedging and insurance strategies
- Regulatory risk: Failure to comply with FDA and international laws may cause recalls, fines, criminal penalties, or halt of product distribution
- Operational risk: Supply chain disruptions from limited single source suppliers, geopolitical conflicts, or tariffs risking delays and increased costs
- Financial risk: Exposure to fluctuations in foreign currency exchange rates impacting results; effects compounded by inflation and interest rate changes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Revvity quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.